DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
KFF - 2 they’ve - 1 ” Drew Altman - 1 Dr - 1 Sanjay Gupta - 1 ” - 1 Mounjaro - 1 ” KFF - 1
Top related locs:
KFF U.S United States
Top related orgs:
CNN - 2 Health - 1 CNN Health - 1 Medicare - 1 US Food and Drug Administration - 1 Congressional - 1

Search resuls for: "” KFF"


2 mentions found


☆ LGBT adults in the US are twice as likely to experience disrespect or unfair treatment at the doctor’s office, survey finds
  + stars: | 2024-04-02 | by ( Deidre Mcphillips | ) edition.cnn.com   time to read: +4 min
Less than 20% of adults who do not identify as LGBT say they have experienced any of these same interactions. Consequences resulting from these negative health care experiences are also more than twice as common among LGBT adults. About a quarter of LGBT adults say they’ve had a recent health care experience that caused their health to get worse, compared with less than 10% of other adults, the survey found. LGBT adults are consistently more likely than non-LGBT adults to experience discrimination in their daily lives at least a few times a year across demographics. But among LGBT adults, negative experiences are more likely among those who are younger, women and have lower income.
Persons: they’ve, ” Drew Altman, KFF, Dr, Sanjay Gupta, ” Organizations: CNN, Health, CNN Health Locations: KFF, U.S, United States
☆ Medicare spending on Ozempic and similar diabetes drugs soars, study finds, and it could end up costing seniors
  + stars: | 2024-03-26 | by ( Tami Luhby | ) edition.cnn.com   time to read: +2 min
CNN —Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis. Medicare began covering Ozempic for people with diabetes in 2018, with Rybelsus and Mounjaro joining in 2019 and 2022, respectively. The KFF study examined gross spending, which does not take into account any rebates paid by drug manufacturers that would lower Medicare spending. The drugs’ popularity and prices could end up raising costs for both the federal government and Medicare enrollees broadly. Medicare could choose Ozempic and Rybelsus for its drug negotiation program as early as 2025, KFF wrote, which could lower spending on the medications.
Persons: Mounjaro, ” KFF, KFF Organizations: CNN, Medicare, US Food and Drug Administration, Congressional
0 next >>
Total: 2